Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Gemcitabine + Cisplatin in Nasopharyngeal Cancer
NCT03924986Phase 3Completed
- Sponsor
- BeiGene
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Tislelizumab + Gemcitabine + Cisplatin with Placebo + Gemcitabine + Cisplatin (2 arms). Primary endpoint: Progression-free Survival (IRC) at 23 months. Started Mar 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03924986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924986.